163 related articles for article (PubMed ID: 16896050)
1. MDM2 SNP309 and SNP354 are not associated with lung cancer risk.
Pine SR; Mechanic LE; Bowman ED; Welsh JA; Chanock SC; Shields PG; Harris CC
Cancer Epidemiol Biomarkers Prev; 2006 Aug; 15(8):1559-61. PubMed ID: 16896050
[TBL] [Abstract][Full Text] [Related]
2. Associations between the MDM2 promoter P1 polymorphism del1518 (rs3730485) and incidence of cancer of the breast, lung, colon and prostate.
Gansmo LB; Vatten L; Romundstad P; Hveem K; Ryan BM; Harris CC; Knappskog S; Lønning PE
Oncotarget; 2016 May; 7(19):28637-46. PubMed ID: 27081698
[TBL] [Abstract][Full Text] [Related]
3. MDM2 SNP285 does not antagonize the effect of SNP309 in lung cancer.
Ryan BM; Calhoun KM; Pine SR; Bowman ED; Robles AI; Ambs S; Harris CC
Int J Cancer; 2012 Dec; 131(11):2710-6. PubMed ID: 22487911
[TBL] [Abstract][Full Text] [Related]
4. Influence of MDM2 SNP309 and SNP285 status on the risk of cancer in the breast, prostate, lung and colon.
Gansmo LB; Knappskog S; Romundstad P; Hveem K; Vatten L; Lønning PE
Int J Cancer; 2015 Jul; 137(1):96-103. PubMed ID: 25431177
[TBL] [Abstract][Full Text] [Related]
5. Association of breast cancer outcome with status of p53 and MDM2 SNP309.
Boersma BJ; Howe TM; Goodman JE; Yfantis HG; Lee DH; Chanock SJ; Ambs S
J Natl Cancer Inst; 2006 Jul; 98(13):911-9. PubMed ID: 16818855
[TBL] [Abstract][Full Text] [Related]
6. MDM2 SNP309 polymorphism is associated with colorectal cancer risk.
Wang W; Du M; Gu D; Zhu L; Chu H; Tong N; Zhang Z; Xu Z; Wang M
Sci Rep; 2014 May; 4():4851. PubMed ID: 24797837
[TBL] [Abstract][Full Text] [Related]
7. MDM2 and CDKN1A gene polymorphisms and risk of Kaposi's sarcoma in African and Caucasian patients.
Tornesello ML; Buonaguro L; Cristillo M; Biryahwaho B; Downing R; Hatzakis A; Alessi E; Cusini M; Ruocco V; Viviano E; Romano N; Katongole-Mbidde E; Buonaguro FM
Biomarkers; 2011 Feb; 16(1):42-50. PubMed ID: 20979563
[TBL] [Abstract][Full Text] [Related]
8. Results based on 124 cases of breast cancer and 97 controls from Taiwan suggest that the single nucleotide polymorphism (SNP309) in the MDM2 gene promoter is associated with earlier onset and increased risk of breast cancer.
Sun YF; Leu JD; Chen SM; Lin IF; Lee YJ
BMC Cancer; 2009 Jan; 9():13. PubMed ID: 19144119
[TBL] [Abstract][Full Text] [Related]
9. Associations of MDM2 SNP309, transcriptional activity, mRNA expression, and survival in stage I non-small-cell lung cancer patients with wild-type p53 tumors.
Chien WP; Wong RH; Cheng YW; Chen CY; Lee H
Ann Surg Oncol; 2010 Apr; 17(4):1194-202. PubMed ID: 19941079
[TBL] [Abstract][Full Text] [Related]
10. A cohort study on the association of MDM2 SNP309 with lung cancer risk in Bangladeshi population.
Reza HA; Anamika WJ; Chowdhury MMK; Mostafa MG; Uddin MA
Korean J Intern Med; 2020 May; 35(3):672-681. PubMed ID: 32392664
[TBL] [Abstract][Full Text] [Related]
11. Association of a functional polymorphism in the promoter of the MDM2 gene with risk of nonsmall cell lung cancer.
Lind H; Zienolddiny S; Ekstrøm PO; Skaug V; Haugen A
Int J Cancer; 2006 Aug; 119(3):718-21. PubMed ID: 16496380
[TBL] [Abstract][Full Text] [Related]
12. Effect of MDM2 SNP309 and p53 codon 72 polymorphisms on lung cancer risk and survival among non-smoking Chinese women in Singapore.
Chua HW; Ng D; Choo S; Lum SS; Li H; Soh LY; Sabapathy K; Seow A
BMC Cancer; 2010 Mar; 10():88. PubMed ID: 20219101
[TBL] [Abstract][Full Text] [Related]
13. MDM2 promoter SNP309 is associated with an increased susceptibility to chronic lymphocytic leukemia and correlates with MDM2 mRNA expression in Chinese patients with CLL.
Dong HJ; Fang C; Fan L; Zhu DX; Wang DM; Zhu HY; Zhuang Y; Miao KR; Liu P; Xu W; Li JY
Int J Cancer; 2012 May; 130(9):2054-61. PubMed ID: 21647873
[TBL] [Abstract][Full Text] [Related]
14. Cigarette smoking, MDM2 SNP309, gene-environment interactions, and lung cancer risk: a meta-analysis.
Bai J; Dai J; Yu H; Shen H; Chen F
J Toxicol Environ Health A; 2009; 72(11-12):677-82. PubMed ID: 19492228
[TBL] [Abstract][Full Text] [Related]
15. MDM2 promoter polymorphism is associated with increased susceptibility to hepatocellular carcinoma in Turkish population.
Akkiz H; Sümbül AT; Bayram S; Bekar A; Akgöllü E
Cancer Epidemiol; 2010 Aug; 34(4):448-52. PubMed ID: 20447891
[TBL] [Abstract][Full Text] [Related]
16. Lack of association between MDM2 promoter SNP309 and clinical outcome in patients with neuroblastoma.
Rihani A; Van Maerken T; De Wilde B; Zeka F; Laureys G; Norga K; Tonini GP; Coco S; Versteeg R; Noguera R; Schulte JH; Eggert A; Stallings RL; Speleman F; Vandesompele J
Pediatr Blood Cancer; 2014 Oct; 61(10):1867-70. PubMed ID: 24391119
[TBL] [Abstract][Full Text] [Related]
17. Association between a functional single nucleotide polymorphism in the MDM2 gene and sporadic endometrial cancer risk.
Walsh CS; Miller CW; Karlan BY; Koeffler HP
Gynecol Oncol; 2007 Mar; 104(3):660-4. PubMed ID: 17123590
[TBL] [Abstract][Full Text] [Related]
18. A functional SNP in the MDM2 promoter, pigmentary phenotypes, and risk of skin cancer.
Nan H; Qureshi AA; Hunter DJ; Han J
Cancer Causes Control; 2009 Mar; 20(2):171-9. PubMed ID: 18814047
[TBL] [Abstract][Full Text] [Related]
19. Current evidence on the relationship between SNP309 polymorphism in the MDM2 gene and colorectal cancer risk.
Fu Q; Zhang G; Chen H; Zheng Y; Cheng J
Tumour Biol; 2013 Dec; 34(6):3721-9. PubMed ID: 23912932
[TBL] [Abstract][Full Text] [Related]
20. MDM2 promoter SNP55 (rs2870820) affects risk of colon cancer but not breast-, lung-, or prostate cancer.
Helwa R; Gansmo LB; Romundstad P; Hveem K; Vatten L; Ryan BM; Harris CC; Lønning PE; Knappskog S
Sci Rep; 2016 Sep; 6():33153. PubMed ID: 27624283
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
